An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Latest Information Update: 06 Jun 2025
At a glance
- Drugs Ivosidenib (Primary)
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Registrational
- Acronyms ProvIDHe
- Sponsors Servier
Most Recent Events
- 29 May 2023 New trial record